dence indicates a role of PAR 2 in the development of various inflammatory diseases (reviewed in Refs. 1, 2). The impact of PAR 2 activation on inflammation can be variable, in some instances leading to proinflammatory effects (4, 5) , and in other settings to an anti-inflammatory protective effect (6, 7) .
In mice, PAR 2 expression in airways is enhanced upon infection with influenza A virus, pointing to the involvement of this receptor in the pathogenesis of viral disease (8) . Moreover, PAR 2 -expressing mononuclear cells were found to infiltrate the infected airway tissues during influenza viral infection (8) . Nonetheless, the precise role of PAR 2 in regulating monocyte function during influenza A virus infection has not been evaluated in any depth.
Upon infection, human monocytes/macrophages release immunoactive mediators (for example, IL-18 and IFN␣/␤) directing infiltrating cells (monocytes and lymphocytes) to the site of infection and inducing anti-viral activities (9, 10) . Macrophage-derived IFN␣/␤ and IL-18 regulate production of IFN-␥ by T and NK cells (11) . This cytokine, in turn, enhances monocyte/macrophage activation acting on production of anti-viral mediators and expression of cell surface molecules involved in ingestion of opsonized viral particles and in process of monocyte transmigration (Fc␥RI and ␣V␤3, respectively) (10, 12, 13) .
IFNs, originally discovered as agents that interfere with viral replication, are now well-known as immune mediators with a wide range of functions. IFNs amplify anti-viral mechanisms affecting cleavage and "editing" of viral RNA, inhibition of protein synthesis, and transcription (reviewed in Ref. 14) . Although the immunomodulatory activity of IFN-␥ is often considered as its primary function, this cytokine is also very important for establishing an effective anti-viral defense (15) . Because of its recognized ability to regulate an inflammatoryprotective response, we wondered whether PAR 2 might synergize with the actions of IFN-␥.
In the present study, we hypothesized that PAR 2 agonists may act along with IFN-␥ to enhance the suppression of viral replication and to increase the production of an inflammatory cytokine like IFN-␥-inducible protein 10 kDa (IP-10). We also hypothesized that PAR 2 agonist would enhance IFN-␥-induced up-regulation of the expression on monocyte cell surface of ␣V␤3 integrin and CD64 (Fc␥RI), the molecules that participate in migration of monocytes toward opsonized virus particles. To test these hypotheses, we measured the viral yield of influenza A-infected monocytes treated with a PAR 2 agonist and IFN-␥ either alone or in combination, and we measured the production of IP-10 by the cells. We also determined the cell surface expression of CD64 (Fc␥RI) and ␣V␤3 integrin in monocytes treated with the same two agonists either alone or in combination.
Materials and Methods

Materials
Human rIFN-␥ was purchased from TebuBio. Trypsin was purchased from Sigma-Aldrich. Human PAR 2 activating peptide with the sequence transcinnamoyl-LIGRLO-NH 2 (cAP) and reverse peptide with sequence transcinnamoyl-OLRGIL-NH 2 (cRP) (from Dr. McMaster, University of Calgary, Calgary, Canada) were used as described previously (16) . The following mAbs were used: unconjugated mouse anti-human PAR 2 (clone SAM-11) (Santa Cruz Biotechnology), mouse anti-human CD64 (Dako), mouse anti-human ␣V␤3 (Chemicon International), mouse anti-human IB␣ (Imgenex), as well as mouse anti-human ␤-Actin (Sigma-Aldrich). HRP-conjugated sheep anti-mouse Ab was obtained from Amersham Biosciences, and PE-conjugated goat anti-mouse Ab was obtained from Jackson ImmunoResearch Laboratories. Cell culture reagents were from BioWhittaker, PromoCell, and Life Technologies. fMLP was purchased from Sigma-Aldrich. Fura-2 acetoxymethyl ester was from Invitrogen. Avian influenza virus A/FPV/Bratislava/79 (H7N7) (FPV) was taken from the depository of the Institute of Molecular Virology, Münster, Germany.
Isolation and culture of human monocytes
Blood for in vitro experiments with human monocytes was obtained from healthy adult volunteers in buffy-coats (Deutsches Rotes Kreuz). Monocytes were isolated by Biocoll (Biochrom) density gradient centrifugation and subsequent negative selection by using magnetic cell sorting and Monocyte Isolation kit II (depletion method) according to the manufacturer's instructions (Miltenyi Biotech). Isolated monocytes were cultured in RPMI 1640 medium supplemented with 0.9% FCS, 1% penicillin/streptomycin, 2 mM L-glutamine, and 1% nonessential amino acids. Monocytes were cultured at a concentration of 1 ϫ 10 6 cells per 1.5 ml of medium. After isolation cells were equilibrated (37°C, 5% CO 2 ) for a two hour period to allow for recovery before use in the experiments. IFN-␥ was used at a concentration of 200 U/ml; trypsin was used at a concentration of 5 ϫ 10 Ϫ8 M, which is known to be efficient for human granulocyte stimulation (16); PAR 2 -tc-activating peptide (PAR 2 -cAP) was used at concentrations of 1 ϫ 10 Ϫ5 M, 5 ϫ 10 Ϫ5 M, 1 ϫ 10 Ϫ4 M, and 2 ϫ 10 Ϫ4 M as described in the Results section and figure legends. The corresponding reverse peptide with the reverse-sequence (PAR 2 -cRP) was used at concentration of 1 ϫ 10 Ϫ4 M and served as a negative control.
Measurement of cytosolic calcium levels
PAR 2 signaling was assessed by measuring cAP-induced Ca 2ϩ mobilization. Monocytes were washed, resuspended in HEPES-buffered salt solution (140 mM NaCl, 3 mM KCl, 0.4 mM Na 2 HPO 4 , 10 mM HEPES, 5 mM glucose, 1 mM MgCl 2 , and 0.8 mM CaCl 2 (pH 7.4)), and incubated with 3.5 M fura-2 acetoxymethyl. Cells were washed twice and resuspended in prewarmed buffer solution. One million cells were transferred to a microcuvette, and the fluorescence of sample was measured at 340 and 380 nm excitation and 510 nm emission in a FluoroMaxx spectrophotometer (Yobin Yvon). The ratio of the fluorescence at the two excitation wavelengths, which is proportional to [Ca 2ϩ ] i , was calculated.
SDS-PAGE and immunoblot analysis
Whole cell lysates (1 ϫ 10 6 cells per lane) were separated by SDS-PAGE and blotted onto nitrocellulose membranes (Amersham Biosciences). Membranes were immunostained with either mouse anti-human IB␣ (1 g/ml) or mouse anti-human ␤-Actin (1/2000), and subsequently with sheep anti-mouse HRP (1/3000). Proteins labeled with Ab complexes were visualized using the SuperSignal West Pico ECL detection kit (Pierce).
Virus infections and determination of virus titers in plaque assays
Infection experiments were performed according to the following schemes. In the first scheme of experiments, human monocytes were pretreated for 2 h with PAR 2 -cAP, PAR 2 -cRP, IFN-␥, or their combination, and also further stimulated with these substances subsequent to infection with influenza A virus. In the second experimental scheme, human monocytes were only pretreated for 2 h with specified concentrations of trypsin, PAR 2 -cAP, PAR 2 -cRP, IFN-␥, or their combination. Further application of substances during virus amplification period was not performed in these experiments.
After the 2 h prestimulation, medium was removed. Cells were washed and were subsequently incubated with influenza virus A/FPV/Bratislava/79 (FPV) at a multiplicity of infection (MOI) of 0.05 diluted in PBS containing 0.01% CaCl 2 , 0.01% MgCl 2 , and 0.2% BSA. Incubation was performed for 30 min at 37°C and 5% CO 2 . Inoculum was aspirated, and monocytes were cultured with or without stimulation in RPMI 1640 supplemented with 2 mM L-glutamine, 1% non essential amino acids, 1% penicillin and streptomycin, 0.2% BSA, 0.01% CaCl 2 , and 0.01% MgCl 2 (here and further "medium for infection"). In the case of stimulated samples, the RPMI 1640 additionally contained PAR 2 -cAP or PAR 2 -cRP, IFN-␥, or their combination. Aliquots (400 l) of the medium were collected at 20 h after infection. Viral replication was determined by a standard plaque assay on confluent Madin-Darby canine kidney cells.
FACS of CD64, ␣V␤3, and PAR 2 cell surface expression on human monocytes
For one-color FACS analysis, 1 ϫ 10 6 monocytes were used. Noninfected monocytes were stimulated with PAR 2 -cAP, PAR 2 
ELISA and chemokine arrays
To generate supernatants from noninfected monocytes, 1 ϫ 10 6 cells were treated with the indicated stimulus for 2 or 16 h, respectively. Supernatants from FPV-infected monocytes were prepared as described above; however, monocytes were pretreated with PAR 2 -cAP, PAR 2 
Statistical analysis
Results are expressed as mean Ϯ SEM. At least three independent experiments have been performed (n Ͼ 3). Statistical evaluation was performed by paired t test (two tails), sign test (only for plaque assay data as an additional statistical test), or Wilcoxon test. Significance was assigned where p Ͻ 0.05.
Results
PAR 2 -cAP induces [Ca 2ϩ ] i increase in purified human monocytes
Previously, it was demonstrated that cAP induces an increase in [Ca 2ϩ ] i in human neutrophils (16) . Human primary monocytes are known to express PAR 2 mRNA (17, 18) , and, in our study, we wanted to confirm that cAP is able to activate PAR 2 expressed by human monocytes. Application of cAP at a concentration of 10
Ϫ4
M induced an increase in intracellular Ca 2ϩ (Fig. 1, A and B) . In contrast, treatment of human monocytes with the PAR 2 -inactive reverse-sequence peptide cRP (10 Ϫ4 M) failed to cause a response ( Fig. 1, A and B) . Thus, human monocytes efficiently respond to PAR 2 -cAP with a specific [Ca 2ϩ ] i increase.
Effects of PAR 2 -cAP and IFN-␥ on viral replication in isolated human monocytes
In murine epithelial cells, the expression of PAR 1 and PAR 2 was enhanced during influenza A virus infection (8) . Furthermore, IFN-␥ expression increases during influenza viral infection of human monocytes (19) . However, a precise role of PAR 2 activation for viral replication and the ability of PAR 2 agonist to enhance IFN-␥-induced protective effects remained unexplored. In the first series of experiments, we pretreated cells for 2 h with PAR 2 -cAP, IFN-␥, or both before infection with influenza A virus, and also applied these stimuli or their combination during virus replication period (see the description of the first experimental scheme in Materials and Methods for details). In comparison with untreated monocytes, treatment with either the PAR 2 -cAP (at concentration of 1 ϫ 10 Ϫ4 M) or IFN-␥ (200 U/ml) alone decreased progeny virus titers by ϳ73 Ϯ 3 and 70 Ϯ 9%, respectively. The combined treatment with the same concentrations of IFN-␥ and PAR 2 -cAP together enhanced the IFN-␥-induced effect and resulted in greater decrease the number of viral particles (92 Ϯ 2% reduction the number of viral particles as compared with untreated cells) ( Fig.  2A) . In contrast, the control PAR 2 -cRP (1 ϫ 10 Ϫ4 M) did not exert any effect on viral replication when it was applied either alone or in combination with IFN-␥ ( Fig. 2A) . To reveal the dose-dependence of the observed cAP effect, we performed a series of experiments with lower (1 ϫ 10 Ϫ5 M and 5 ϫ 10 Ϫ5 M) and higher (2 ϫ 10 Ϫ4 M) concentrations of PAR 2 -cAP ( Fig.  2B) . At concentrations 1 ϫ 10 Ϫ5 M or 5 ϫ 10 Ϫ5 M, PAR 2 -cAP did not significantly affect influenza A virus replication and also was not able to enhance IFN-␥-induced anti-viral effect (Fig.  2B) . The higher concentration of cAP (2 ϫ 10 Ϫ4 M) was not more beneficial and protective against viral replication than the concentration used in the first series of experiments (1 ϫ 10 Ϫ4 M) (compare Fig. 2, A and B) . Compared with untreated cells, application of PAR 2 -cAP at a concentration of 2 ϫ 10 Ϫ4 M decreased virus titers by 48 Ϯ 14%, whereas combined treatment of 2 ϫ 10 Ϫ4 M cAP together with IFN-␥ reduced virus replication by 93 Ϯ 0.9% (Fig. 2B) . Thus, we confirmed that viral-suppressing activity PAR 2 -cAP is reached at concentration 10 Ϫ4 M and higher concentrations are not more beneficial. Classical enzymatic PAR 2 agonists (trypsin and tryptase) are known to promote directly influenza A virus replication due to their ability to cleave viral hemagglutinin and induce its maturation (20, 21) . This fact limited the use of proteases in the first series of experiments, in which both pretreatment and stimuli application during virus amplification period were used. Therefore, we performed an additional series of experiments based only on prestimulation of monocytes with trypsin (5 ϫ 10 Ϫ8 M), PAR 2 -cAP (1 ϫ 10 Ϫ4 M), IFN-␥ (200 U/ml), or their combination, without application of these stimuli during viral amplification period (Fig. 2C) . However, only the pretreatment of human monocytes with either trypsin or PAR 2 -cAP was not protective against influenza A virus replication. Moreover, combined application of trypsin or PAR 2 -cAP along with IFN-␥ for 2 h before virus infection did not enhance IFN-␥-induced suppression of influenza A virus replication (Fig. 2C) . Thus, PAR 2 agonist pretreatment by itself (without agonist application during viral replication) could not efficiently protect human monocytes against viral replication.
Simultaneous application of PAR 2 -cAP and IFN-␥ reduces IB␣ degradation in human monocytes
Recently, active NF-B signaling has been demonstrated to be a prerequisite for efficient influenza A virus infection of human cells (22, 23) . The inhibitory subunit, IB␣, maintains NF-B in an inactive state and is degraded in the course of NF-B activation. Therefore, we studied whether PAR 2 -cAP (1 ϫ 10 Ϫ4 M) and IFN-␥ (200 U/ml) might have an effect on IB␣ levels in purified monocytes. Activation of cells with the PAR 2 agonist had a biphasic impact on the abundance of IB␣, leading to a rapid early decrease in levels at 15 min and an increased level at 30 min that returned to basal levels at ϳ2 h after PAR 2 agonist application. In contrast, treatment with IFN-␥ had little effect on the levels of IB␣ at 15 and 30 min (Fig. 3, A and B) and caused only an increase in levels at 2 h (Fig. 3C) . However, in the presence of both PAR 2 -cAP and IFN-␥ the level of IB␣ was increased above baseline at all time points (Fig. 3, A-C) .
PAR 2 -cAP stimulation enhanced IFN-␥-induced IP-10 release from influenza A-infected as well as noninfected human monocytes
We also investigated whether PAR 2 agonist application affects IFN-␥-induced changes of chemokine production in monocytes. Enhanced production of IP-10 after monocyte stimulation with IFN-␥ is known to attract T lymphocytes and, subsequently, to modulate adaptive immune responses (24) . To study the effects of PAR 2 -cAP (10 Ϫ4 M), PAR 2 -cRP (10 Ϫ4 M), and IFN-␥ (200 U/ml) application on chemokine release by human monocytes, we treated cells for 2 or 16 h with the indicated stimulus alone or in combination. Collected cell culture supernatants were further used for chemokine arrays and ELISAs. We were not able to detect any significant difference in IP-10 secretion by human monocytes after stimuli application during 2 h (data not shown). However at 16 h after treatment, we demonstrated that coapplication of IFN-␥ and PAR 2 -cAP enhances the increase of IP-10 release induced by IFN-␥ alone in noninfected monocytes (Fig. 4A ). Untreated and PAR 2 -cAP-treated noninfected monocytes did not release IP-10 above the threshold level detectable by chemokine array (Fig. 4A) . Using ELISA we performed quantitative analysis of IP-10 release in noninfected as well as infected monocytes. The level of IP-10 release in influenza A virus-infected monocytes, without application of any other stimuli, was 149 Ϯ 60 pg/ml (Fig. 4B) . Untreated, noninfected monocytes released IP-10 in a concentration of 9.8 Ϯ 4.3 pg/ml (Fig. 4C) . PAR 2 -cAP alone just slightly enhanced IP-10 release in influenza A virus-infected monocytes (Fig. 4B) . However, the effect of PAR 2 -cAP on IP-10 release by noninfected cells was not significant (Fig. 4C) . Coapplication of IFN-␥ and PAR 2 -cAP in influenza A virus-infected monocytes enhanced the IFN-␥-induced effect at ϳ2-fold (Fig. 4B, right) . In noninfected cells, costimulation with PAR 2 -cAP increased IFN-␥-induced effects ϳ10-fold (Fig. 4C, right) . In contrast, application of PAR 2 -cRP alone as well as in combination with IFN-␥ did not result in any significant changes of IP-10 production by human monocytes (Fig. 4 , B and C) (data not shown).
Stimulation with IFN-␥ enhances PAR 2 cell surface expression on human noninfected monocytes
Nystedt and colleagues (25) reported that stimulation of human endothelial cells with TNF-␣ or IL-1␣ elevated the expression of PAR 2 mRNA in these cells. IFN-␥ could modulate the level of certain proinflammatory cytokines (TNF-␣ and IL-1␣) (26) . However, a regulatory role of IFN-␥ on PAR 2 expression levels is unknown. In this study, we report that the stimulation of isolated noninfected human monocytes with IFN-␥ enhances PAR 2 cell surface expression in these cells. The display of PAR 2 at monocyte cell surface was enhanced at 4 and 8 h after exposure to IFN-␥ (the mean fluorescence intensity (MFI) increases at 63 Ϯ 21 and 94 Ϯ 12%, respectively) (Fig. 5, A and B) .
PAR 2 cell surface expression on human monocytes decreases during influenza A infection
To investigate whether influenza A infection affects cell surface expression of PAR 2 on human monocytes, we assessed time-dependent changes of PAR 2 display after virus infection of these cells (Fig. 5C) . At 4 and 8 h after infection, PAR 2 expression did not change significantly (Fig. 5C) . However, influenza A virus infection reduced PAR 2 display on monocytes at 12 h after infection (the number of PAR 2 positive cells decreased at 38 Ϯ 13%) (Fig. 5C ). Among noninfected human monocytes, 90 Ϯ 3% were PAR 2 positive cells.
Coapplication of PAR 2 -cAP and IFN-␥ enhances IFN-␥-induced changes of CD64 (Fc␥RI) and ␣V␤3 integrin expression on the cell surface of human noninfected monocytes
CD64 is known to play an important role in opsonized phagocytosis during influenza A virus infection (12) . The ␣V␤3 integrin is reported to facilitate leukocyte transmigration through the inflammatory endothelium (13). Thus, both receptors are known to play important roles in host defense during an infection. We investigated whether treatment with the PAR 2 -cAP (1 ϫ 10 Ϫ4 M) might enhance the known effects of IFN-␥ on the cell surface expression of both receptors on human monocytes. Monocytes were treated with the IFN-␥ and/or PAR 2 -cAP during 6 or 12 h. Significant effects were detected only at the 12-h time point. Exposure to PAR 2 -cAP alone did not lead to a significant change of ␣V␤3 cell surface display as compared with untreated monocytes (Fig. 6A) . However, treatment of noninfected monocytes with IFN-␥ enhanced ␣V␤3 cell surface expression (MFI increases at ϳ100% as compared with untreated cells) (Fig. 6A) . Further, treatment with a combination of PAR 2 -cAP and IFN-␥ caused an enhancement of cell surface ␣V␤3 compared with cells treated with IFN-␥ alone (the MFI increases at 165 Ϯ 19% as compared with control cells) (Fig. 6A) . A similar enhancement by PAR 2 agonist coapplication was observed for the IFN-␥-induced up-regulation of cell surface expression of CD64 (after application of IFN-␥ alone, MFI increased at 54 Ϯ 16% as compared with untreated monocytes; after coapplication of both stimuli, PAR 2 -cAP and IFN-␥, MFI increased at 94 Ϯ 20% as compared with untreated cells) (Fig.  6B) . The treatment of monocytes with PAR 2 -cRP either alone or in combination with IFN-␥ did not have any impact on ␣V␤3 as and CD64 cell surface display (data not shown).
Discussion
The main finding of our work is that combined application of PAR 2 agonist along with IFN-␥ is able to enhance the anti-viral effects of cytokine on human monocytes: 1) to increase IFN-␥-mediated reduction in viral replication, 2) to increase the release of protective monocyte cytokines like IP-10 that can attract monocytes and T lymphocytes to the site of viral infection, and 3) to increase monocyte surface expression of CD64 (Fc␥RI) and ␣V␤3 that would enhance the opsonization of virus and promote the migration of monocytes across the endothelial barrier to populate the virus-infected tissue. Moreover, the treatment of human monocytes shortly before and during viral infection with synthetic PAR 2 agonist alone reduced influenza A replication in these cells. The nature of these results limited the use of trypsin and tryptase, classical PAR 2 activating proteases, in our study. Both, trypsin and tryptase could mediate PAR 2 -independent effects apart from those associated with receptor activation (27, 28) . Moreover, trypsin as well as tryptase could directly promote influenza A replication due to the ability of these enzymes to cleave viral hemagglutinin and induce its maturation (20, 21) . Thus, taking into account the data of our study, as well as well-documented features of trypsin and tryptase, one might assume that the use of only specific PAR 2 agonist, which is not able to affect hemagglutinin maturation, could be beneficial during influenza A infection. Currently, synthetic PAR 2 peptide agonist satisfies these conditions. Whether any of the proteases might also meet these conditions should be clarified in future studies. The use of reliable commercial PAR 2 antagonist in such studies could also be very helpful, and we hope that such antagonist will be very soon available for the researchers in PAR field.
Human influenza A virus causes a severe disease of the upper respiratory tract. This virus is able to replicate not only in epithelial cells, but also in monocytes/macrophages (29) . Replication of human influenza A virus in monocytes promotes viral spreading through a host body. IFNs were used for prophylaxis against experimentally induced influenza A virus infection in humans and mice (30, 31) . It was our working hypothesis, based on recently published data (8) , that application of PAR 2 agonist could also play a role in the suppression of influenza A virus replication. Short pretreatment and further application of stimuli during infection allowed us to mimic such a situation, in which IFNs are applied for prophylaxis against influenza A virus infection. Indeed, under such conditions, both PAR 2 -cAP and IFN-␥ were able to suppress influenza A virus replication in human monocytes. However, only PAR 2 -cAP pretreatment (in contrast to pretreatment with IFN-␥) was not sufficient for suppression of influenza A virus replication in human monocytes.
The susceptibility of cells to influenza A virus is known to depend on the level of NF-B activation (22, 23) . Normally, IB␣ silences NF-B activation. The phosphorylation and degradation of IB␣, upon cell stimulation, makes NF-B free to trigger transcriptional events. The level of cytoplasmic IB␣, therefore, may serve as an indirect indicator of the level of active NF-B. In our study, the coapplication of PAR 2 -cAP and IFN-␥ enhanced the availability of cytoplasmic IB␣ at all investigated time points (15 min, 30 min, and 2 h). Therefore, the reduction of influenza A virus replication in human monocytes after coapplication of PAR 2 -cAP and IFN-␥ correlates with enhanced availability of cytoplasmic IB␣. This finding suggests that combined PAR 2 -cAP and IFN-␥ stimulation results in a cellular milieu in which the activation of NF-B would be attenuated. Such reduction of NF-B activation could be one of the reasons for the impact, which coapplication of PAR 2 agonist and IFN-␥ has on influenza A virus replication in human monocytes.
Huber and colleagues (12) demonstrated a significant contribution of Fc␥RI to anti-viral defense through the ingestion of opsonized influenza A viruses by murine macrophages. Moreover, IFN-␥ stimulation enhances the expression of Fc␥RI on the cell surface of human monocytes (32) . Thus, we investigated whether PAR 2 -cAP affects an IFN-␥-induced effect on Fc␥RI display on monocyte cell surface. Indeed, costimulation of noninfected human monocytes with PAR 2 -cAP and IFN-␥ resulted in a significant increase of Fc␥RI surface expression as compared with monocytes treated with either agonist alone. This finding supports our hypothesis that a PAR 2 agonist and IFN-␥ can work together to enhance anti-viral effects of the cytokine on human monocytes.
We also investigated the ability of PAR 2 -cAP to act on immunomodulatory functions of IFN-␥ in human monocytes. The production of several chemokines increases after IFN-␥ treatment (15) or upon influenza A virus infection of human monocytes (9) . Among these chemokines are attractants for monocytes and T cells, such as IP-10, MIP-1, MCP-1, and RANTES. IP-10 facilitates endothelial-lymphocyte interactions and transmigration of monocytes as well as T cells toward the site of infection or inflammation (33) . Our data demonstrate that PAR 2 agonist stimulation results in an increased IP-10 secretion by influenza A-infected human monocytes. Moreover, we showed that the IFN-␥-induced increase of IP-10 release was enhanced by simultaneous coapplication of PAR 2 -cAP in virus-infected as well as noninfected monocytes. Surprisingly, we also found that the PAR 2 agonist amplifies the ability of IFN-␥ to increase the cell surface expression of the monocyte adhesion molecule, ␣V␤3. This integrin promotes monocyte transmigration process via interaction with PECAM and vitronectin on endothelial cells (13) . Taken together, our findings indicate that coapplication of PAR 2 agonist along with IFN-␥ is able to enhance not only direct anti-viral, but also immunoregulatory effects of the IFN-␥ on functions of human monocytes. In this regard, we also found that IFN-␥ stimulation amplifies the cell surface display of PAR 2 on human monocytes. These coordinated interactions between IFN-␥ and PAR 2 agonists therefore represent a mechanism whereby the anti-viral and/or immunoregulatory effects of IFN-␥ could be enhanced in human monocytes.
In conclusion, our data clearly demonstrate that PAR 2 agonist acting along with IFN-␥ could enhance the protective effect of this cytokine on human monocyte function in vitro. Moreover, even in the absence of IFN-␥ stimulation, we found that the application of PAR 2 -cAP shortly before and during viral amplification reduces influenza A virus replication in human monocytes. Together, these major findings of our work indicate that the application of PAR 2 agonist might have therapeutic potential in the setting of influenza A virus infection.
